| 摘要 |
Disclosed is a combination comprising a first agent that is a Smoothened inhibitor and a second agent that is an mTOR inhibitor, wherein the first agent is 2-[(R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2’]bipyrazinyl-5’-yl]-propan-2-ol (compound B) a pharmaceutically acceptable salt thereof. Examples of mTOR inhibitors are AY-22989, everolimus, CC1-779, AP-23573, MK-8669, AZD-8055, Ku-0063794, OS1- 027 and WYE-125132. The combination is useful inteh treatment of medulloblastoma. |
